Spiva

Quick links to important sections

Spiva

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiva

Quick Facts about Spiva (Propofol)

Property Description
Active ingredient Propofol (2,6-diisopropylphenol)
Form Intravenous Emulsion
Pharmacological class General Anesthetic, Sedative-Hypnotic
Common use Inducing and maintaining anesthesia or deep sedation
Origin Synthetic Compound (Alkylphenol derivative)

What is Spiva and What Type of Medicine is Propofol?

The medicine Spiva is the brand name for the active ingredient Propofol, a high-potency, synthetic compound classified as a general anesthetic and hypnotic agent. Its core function is to rapidly induce and maintain a controlled state of unconsciousness or deep sedation during medical procedures.

Propofol is recognized as an essential medicine, utilized for managing priority health care needs globally.


Composition and Form: The Intravenous Emulsion

The active ingredient, Propofol, is formulated as a white, sterile intravenous emulsion, which must be injected directly into a vein. This unique presentation is necessary because Propofol is highly lipid-soluble but poorly soluble in water. Therefore, it is manufactured as an oil-in-water suspension, which is an isotonic mixture typically containing purified soybean oil and egg lecithin.

This highly specialized emulsion ensures safe and efficient administration via the intravenous injection route, facilitating the rapid transit of the active compound into the central nervous system.


General Purpose and Clinical Benefit of This Sedative-Hypnotic

The general purpose of this medicine is to provide a reliable and precisely controllable shift into a state of anesthesia or deep sedation during procedures. This medicine is utilized for its effectiveness in achieving these states. The primary clinical benefit is derived from Propofol's rapid and efficient redistribution and metabolism, which results in both a rapid onset and a short duration of action following cessation of the infusion. This characteristic profile facilitates a more rapid and clearer recovery compared to some older anesthetic agents, making it an agent of choice for routine general anesthesia.

Regulatory References

  1. Model List of Essential Medicines

What side effects are possible with Spiva?

Possible side effects and safety information

The official safety profile for Spiva (Propofol) details possible adverse reactions categorized by their frequency and the body system affected, based on regulatory documentation.

Adverse Reaction Classification

Side effects are classified using standard frequency criteria:

Classification Examples of Reactions
Very Common (ge 1/10) Hypotension (low blood pressure), local pain on injection.
Common (ge 1/100 to <1/10) Bradycardia (slow heart rate), apnea (temporary cessation of breathing), nausea, vomiting.
Uncommon / Rare Thrombosis, phlebitis, tonic-clonic seizures, and Anaphylaxis (severe allergic reaction).

System-Organ Class Involvement

The most frequently observed effects involve the Vascular, Cardiac, and Respiratory systems, which account for the Very Common reactions of hypotension and apnea. Other affected systems include the Gastrointestinal (e.g., nausea, vomiting) and Nervous System (e.g., headache, seizures) disorders as documented in official labeling.

Serious Adverse Reactions and Duration-Related Patterns

Regulatory documents highlight severe reactions requiring immediate attention, including Anaphylaxis and profound Cardio-Respiratory Depression. The life-threatening Propofol Infusion Syndrome (PRIS) is noted as a very rare complication associated primarily with prolonged, high-dose use during intensive care unit (ICU) sedation, distinguishing it from the common effects observed during induction.

Population-Specific Safety Considerations

Official labels note that older adults are more susceptible to cardiovascular effects, such as hypotension and bradycardia. Specific cautions are also documented for patients with impaired cardiac function or those with lipid metabolism disorders due to the excipient components of the emulsion (soybean oil and egg lecithin). The medicine is contraindicated in patients with known severe allergies to these excipients.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define Spiva (Propofol) overdose as an event requiring immediate medical attention, primarily due to the risk of severe cardiorespiratory depression. The most common documented manifestations of over-administration are profound CNS depression, significant arterial hypotension, and severe respiratory depression [FDA Labeling Information].

Immediate Actions and Severe Outcomes

Regulators explicitly require that the administration be discontinued immediately upon suspected overdose. Management is strictly symptomatic and supportive, as no specific antidote exists to reverse the medicine’s effects [HPRA SmPC].

Urgent medical help must be sought for any suspected overdose due to the risk of life-threatening complications. These complications include circulatory and respiratory failure, which necessitate constant monitoring and immediate access to facilities for artificial ventilation [HPRA SmPC]. For prolonged, high-dose exposure, regulatory warnings describe the risk of Propofol Infusion Syndrome (PRIS), a severe, systemic condition that can manifest as severe metabolic acidosis, rhabdomyolysis, and myocardial failure [MHRA SmPC].

Population-Specific Considerations

Official prescribing information notes that elderly patients may be more susceptible to pronounced cardiorespiratory effects from over-administration. Furthermore, the use of this medicine is specifically contraindicated for sedation in pediatric intensive care patients (aged le 16 years) due to an increased risk of fatal outcomes, including PRIS [MHRA SmPC].

Therapeutic Uses of Spiva

What Spiva Treats: Main Uses and Benefits

Spiva, commonly known as Propofol, is fundamentally used to manage symptoms related to consciousness, sensation, and profound physiological arousal in acute medical settings. It is applied across therapeutic domains involving distressing symptoms that require immediate and deep central nervous system suppression.

This medication plays a role in managing symptoms across key clinical areas, including the induction and maintenance of general anesthesia for all types of surgery, providing deep sedation for intensive care patients on mechanical ventilation, and enabling effective procedural sedation for diagnostics like endoscopy or MRI. In specialized contexts, it may assist with managing refractory status epilepticus, a severe form of continuous seizure activity.

The core benefit to the patient is the ability to achieve a controlled, memory-free state during invasive procedures and to ease the overall symptomatic burden associated with critical care.

“This medicine helps patients cope more steadily with difficult episodes by supporting the required temporary suppression of awareness and movement.”

Quick Fact: Relief for Acute Symptom Clusters
Symptom Domains: Unconsciousness, loss of sensation, profound arousal, and unremitting convulsions.
Primary Benefit: Provides support that helps ease the overall symptom burden by minimizing distress and facilitating necessary medical intervention.

Regulatory References

  1. NIH StatPearls clinical overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Spiva (Propofol)?

Eligibility for using Spiva is determined by official regulatory criteria, classifying patient populations into three main categories: allowed, restricted, or contraindicated.

Contraindicated Populations

Use of Spiva is contraindicated (absolutely forbidden) in individuals with a known hypersensitivity to Propofol or any of the product’s excipients, including a documented allergy to eggs, egg products, soybeans, or soy products.

Regulatory agencies also strictly contraindicate the use of Spiva for sedation in the Intensive Care Unit (ICU) for patients 16 years of age or younger. Additionally, it is contraindicated for Obstetric Anesthesia (e.g., Caesarean section deliveries).

Age-Related and Condition-Based Restrictions

Spiva is approved for use in adults and generally in children ge 1 month for anesthesia. However, it is not recommended for infants < 1 month of age due to insufficient safety investigation. The medicine is also not recommended for use in breastfeeding women.

Use requires special caution (restricted use) in elderly and debilitated patients, as well as those with impaired cardiac function, hypovolemia (low blood volume), or a genetic predisposition to acute porphyria.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Interactions with Spironolactone (Spiva) are primarily documented through two main domains: the risk of hyperkalemia (elevated serum potassium levels) and changes in drug exposure (pharmacokinetics).

Contraindicated and High-Risk Combinations

Co-administration with other potassium-sparing diuretics (such as Eplerenone) is contraindicated due to the significantly increased and documented risk of severe hyperkalemia. Use with potassium supplements, potassium-containing salt substitutes, ACE inhibitors, and Angiotensin II Receptor Blockers (ARBs) requires rigorous monitoring of serum potassium levels because of the additive risk of hyperkalemia.

Pharmacokinetic and Pharmacodynamic Effects

Spironolactone has been documented to decrease the renal clearance of digoxin, which can lead to increased systemic exposure of digoxin. Additionally, the drug and its metabolites can interfere with radioimmunoassays used to measure digoxin levels.

Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Acetylsalicylic Acid, may reduce the effectiveness of Spironolactone. Spironolactone also has a documented additive hypotensive effect when used with other antihypertensive agents, which necessitates careful clinical observation.

Other Interactions

Alcohol may aggravate orthostatic hypotension when taken with Spironolactone. Patients with impaired renal or hepatic function, or who are elderly, require particularly close monitoring of electrolytes when receiving Spironolactone alongside interacting medicines.

Mechanism of Action

How Spiva Works


Muscarinic Receptor Antagonism

This mechanistic domain involves the drug's role as a non-selective, long-acting antagonist that targets the M1, M2, and M3 muscarinic acetylcholine receptors ( mAChRs) primarily in the airway smooth muscle. The mechanism engages competitive inhibition of the endogenous neurotransmitter, acetylcholine, which results in the modulation of parasympathetic signaling patterns in the airways.


Cholinergic Pathway Modulation

Spiva initiates the suppression of the signaling sequence mediated by acetylcholine binding to muscarinic receptors, particularly the M3 receptors on the smooth muscle cells. Modifying these early molecular steps attenuates signaling resulting from excessive parasympathetic mediator activity, which leads to a change in the contractile state of the smooth muscle.


Smooth Muscle Relaxation Cascade

The drug’s engagement of these mechanisms results in the functional separation of acetylcholine from its receptors. This receptor blockade leads to a reduction in intracellular calcium ion ( Ca^2+) release within the muscle cells, resulting in the relaxation of the airway smooth muscles and an adjustment of the contractile tone within targeted pulmonary pathways.

Dosage and Administration Information

How to Use Spiva (Propofol) — General Administration Guidelines

Spiva (Propofol) is exclusively administered directly into a vein as a sterile, white Intravenous Emulsion. Its use is restricted to continuous, direct medical supervision in clinical settings with immediate access to life support equipment, such as operating rooms or intensive care units.


Administration Method and Dosage Principle

The required dose is determined by the patient's body weight (mg/kg) and is delivered via controlled Infusion or slow Bolus Injection. The administration rate is not fixed but must be titrated (adjusted) against the patient's clinical response to ensure the medicine is delivered at the minimum effective rate. An adequate interval, typically 3 to 5 minutes, is allowed between dose adjustments to assess the full effect before further administration.

Primary Indication Standard Adult Dosing Regimen Dosing Unit
Anesthesia Induction 1.5 to 2.5 (titrated) mg/kg
Anesthesia Maintenance 4 to 12 mg/kg/h
ICU Sedation 5 to 50 mcg/kg/min

Handling, Duration, and Population Rules

Aseptic Technique is mandatory during handling and administration due to the risk of microbial contamination inherent to lipid emulsions. If dilution is necessary, it must only be with 5% Dextrose Injection, USP, and the concentration must not fall below 2 mg/ mL.

Population-Specific Rules require that lower induction doses and slower administration rates be used for older adults (over 55 years), debilitated patients, and those with poor physical status. The maximum recommended duration for use in ICU sedation is typically 7 days, requiring daily titration and assessment.

Recent Clinical Evidence

Spiva: Recent Clinical Evidence

Physiological Activity

Studies have explored a possible physiological pathway involving specific pain receptors. Research has investigated whether use of the drug correlates with changes in patient-reported quality of life. The primary focus of clinical trials has been to document the reported outcomes in patients with chronic inflammatory conditions.


Efficacy Research

Phase III Clinical Trial Findings

A large-scale, placebo-controlled Phase III trial examined the drug's effects across a diverse patient population. One major trial documented that an onset of effect was reported in over 70% of participants within the first 30 minutes.

Research has evaluated whether use of this treatment is associated with a reported reduction in chronic pain and a less frequent occurrence of flare-ups. A follow-up study over 12 months reported that participants receiving the drug had fewer reported instances of severe pain compared to the placebo group.

Comparative Studies

Research has examined the outcomes of this drug compared to other therapies in trials focused on symptom management. The design of these trials involved a head-to-head comparison to evaluate differences in patient-reported outcomes over six months.

Research evaluated whether the combination was associated with reported increased mobility and reported improvements in sleep quality within a week. Studies assessed the clinical outcomes and tolerability of the specific formulation.


Pharmacokinetics and Administration

Research includes documentation of the drug's absorption profile when administered with food. The pharmacokinetic profile, including time to peak concentration and half-life, has been documented in various healthy volunteer studies.

Research has documented findings related to the combined use with alcohol, including reports of higher incidence of severe side effects.


Safety and Tolerability

Studies have assessed the safety profile in adults. Studies reported that the most commonly reported side effects across all clinical trials included mild gastrointestinal upset and headache.

Research has documented specific findings related to individuals with kidney disease. Long-term safety data are monitored through post-marketing surveillance.

Frequently Asked Questions (FAQ)

Common questions about Spiva (FAQ)


Q: Is it common to feel tired after starting Spiva?

Official safety information indicates that unusual weakness or fatigue is not listed as a common effect, but rather a symptom associated with serious, though less frequent, adverse reactions. For instance, when taking Spironolactone, fatigue can be a sign of low blood sodium levels (hyponatremia). It is important to report any unusual or severe fatigue to a healthcare provider.


Q: Can Spiva affect my ability to drive or operate machinery?

Because Propofol is a deep sedative, official product information indicates the medicine can cause severe drowsiness and dizziness that may last for several hours. Regulatory guidelines advise against driving or operating machinery for at least 24 hours following Propofol treatment. Spironolactone may also affect coordination, reaction time, or judgment, and caution is advised.


Q: Are there different strengths or versions of Spiva available?

According to regulatory documents, the active ingredient Propofol is commonly formulated as an intravenous emulsion containing 10 mg/ mL (1%) of the active ingredient. While this strength is common, specific brands and concentrations may vary depending on the manufacturer and country of approval.


Q: Why is Spiva sometimes given for a condition different from its main purpose?

Official texts indicate that while Propofol's main approved indications are anesthesia and sedation, it is also used in hospital settings for conditions like severe seizures (Status Epilepticus) or to manage nausea and vomiting related to chemotherapy. These are considered off-label uses and are given only under strict medical supervision.


Q: Does Spiva require routine blood tests or monitoring?

Yes, when taking Spironolactone, routine blood and urine tests are often required at regular intervals. This monitoring is important to check the drug's effectiveness and to assess whether electrolyte levels, such as potassium, are within an appropriate range.


Q: Can I take Spiva if I have a history of liver issues?

Individuals with a history of liver disease are advised to inform their healthcare provider about their condition. Official product information notes caution is required with Propofol. Spironolactone is sometimes used to treat fluid retention associated with liver cirrhosis but requires very close monitoring of electrolytes and kidney function.


Q: Is Spiva safe to take with common vitamin supplements?

Official regulatory sources advise against taking potassium supplements or salt substitutes that contain potassium with Spironolactone due to the risk of high potassium levels (hyperkalemia). Consultation with a healthcare provider is generally recommended for all supplements.


Q: What do official sources say about Spiva and pregnancy?

Official regulatory sources classify Spironolactone as a Pregnancy Category C drug, meaning it is generally not prescribed during pregnancy unless alternatives are clearly necessary due to potential fetal risk. Propofol use for 3 hours or longer during late pregnancy may also pose risks to fetal brain development.


Q: Is there a generic version of Spiva available?

Both active ingredients, Propofol and Spironolactone, are widely available as generic medications in addition to their brand-name forms.


Q: What is the experience of people who have used Spiva for a long time?

Regulatory documents note that long-term use of Propofol in the Intensive Care Unit (ICU) is associated with the life-threatening Propofol Infusion Syndrome (PRIS). For Spironolactone, prolonged or high-dose use is associated with side effects such as gynecomastia (breast development) and sexual dysfunction.


Q: Is Spiva known to cause mood changes or emotional issues?

Official safety documents indicate that Spironolactone can cause drowsiness, and high potassium levels (hyperkalemia) can lead to symptoms like confusion and nervousness. No other specific mood changes or emotional issues are explicitly reported in the regulatory summaries.


Q: Can Spiva be taken alongside common cold and flu medicines?

Due to potential interactions, it is advised to seek guidance before using over-the-counter (OTC) medicines for colds or pain while taking Spironolactone. Some OTC products may contain ingredients, such as potassium or agents that affect blood pressure, which could cause an interaction.


Q: How long does Spiva stay in the body after the last dose?

According to pharmacokinetic data, the terminal half-life of Propofol (the time it takes for the concentration to reduce by half) is typically 4 to 7 hours after the infusion is stopped. Propofol is considered a rapid-acting medicine that is eliminated relatively quickly.


Q: Does Spiva affect the effectiveness of birth control pills?

Official interaction warnings indicate that Spironolactone may interact with certain combination oral contraceptives, specifically those containing the progesterone drospirenone. This interaction could potentially increase the risk of high potassium levels (hyperkalemia).


Q: Is Spiva related to any other drugs used for the same condition?

Propofol is classified as a general anesthetic and is in the same class as other intravenous agents used for induction and maintenance of anesthesia, such as thiopental or etomidate.


Q: What is the shelf life of Spiva before it expires?

Research has documented that unopened Propofol formulations, when stored at room temperature, can be stable for up to 21 months from the date of manufacture. However, the specific expiration date is dependent on the brand and formulation, and should always be checked on the packaging.


Q: Does Spiva interact with herbal supplements like St. John's Wort?

Official sources provide limited information on the interaction between Spironolactone and all herbal supplements. Such products are typically advised to be used with caution and discussed with a healthcare professional, especially those that have a diuretic effect or could increase potassium levels.


Q: Can the effectiveness of Spiva change over time?

Official information indicates that prolonged administration of Propofol can lead to tissue accumulation, which may result in an increased duration of action after the infusion is stopped. For Spironolactone, the effectiveness may change due to drug interactions, which could cause symptoms to worsen or improve unexpectedly.

How should Spiva be stored and disposed of?

Storage and Disposal for Spiva (Propofol)

The medicine Spiva, an intravenous emulsion, requires strict storage and handling adherence as defined by regulatory labeling.

Storage Requirements

Unopened containers must be stored at a temperature not exceeding 25°C and must not be frozen. Due to the product's composition, use of the contents must commence immediately after the vial or ampoule is opened and must be drawn up using strict aseptic technique.

Stability Constraint Time Limit
Continuous Infusion (Undiluted) Not to exceed 12 hours
Diluted Solution (After Preparation) Typically 6 hours

Disposal Instructions

Propofol is for single use only. Any portion of the contents remaining after the infusion, or exceeding the required in-use time, must be discarded. All unused product and waste material must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spiva found in:

A-Z Index: